CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...
Cancer
HutchMed Initiates Rolling NDA Submission for Elunate to US FDA
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...
Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...
Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...
Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China
Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...
Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
Biosion and ImmunoGen Collaborate on Cancer ADCs
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...
Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...